PLA2G4A抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08176(PLA2G4A Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P08176(PLA2G4A Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The PLA2G4A antibody targets the phospholipase A2 group IVA (PLA2G4A) protein, also known as cytosolic phospholipase A2 alpha (cPLA2α). This enzyme plays a pivotal role in inflammation and cellular signaling by catalyzing the hydrolysis of membrane phospholipids to release arachidonic acid, a precursor for pro-inflammatory mediators like prostaglandins and leukotrienes. cPLA2α is calcium-dependent and selectively acts on sn-2 acyl bonds of glycerophospholipids, distinguishing it from other phospholipase A2 family members. Its activity is tightly regulated by phosphorylation and intracellular calcium levels, linking it to pathways activated by cytokines, growth factors, and stress stimuli.

PLA2G4A antibodies are essential tools in studying the enzyme’s expression, localization, and function in physiological and pathological contexts. Researchers use these antibodies in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to explore cPLA2α’s involvement in diseases like cancer, neurodegenerative disorders, and chronic inflammation. Elevated cPLA2α levels are associated with conditions such as rheumatoid arthritis, atherosclerosis, and asthma, making it a potential therapeutic target. Inhibitors of cPLA2α are under investigation for anti-inflammatory therapies, and PLA2G4A antibodies aid in validating target engagement and mechanistic studies. Additionally, these antibodies help elucidate the enzyme’s role in lipid metabolism, membrane remodeling, and apoptosis. By enabling precise detection, PLA2G4A antibodies contribute to understanding how cPLA2α dysregulation drives disease progression and inform strategies for modulating its activity in therapeutic contexts.